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Abstract: Antibiotics offer great benefits by reducing the duration and severity of illnesses and 
aiding in infection transmission control. With this being said, the inexorable process of antimicro-
bial drug resistance is to some degree unavoidable. Although drug resistance will likely persist 
and is to be expected, the overall level can be dramatically decreased with increased attention to 
antibiotic overuse and the pharmacokinetic and pharmacodynamic properties of different drug 
formulations, and the use of proper hygiene and protective barriers.   Implementation of such 
practices as microbial surveillance and prophylaxis has been shown to result in decreased hospital 
length of stay, health care costs and mortality due to drug-resistant infections. This review will 
summarize current progress in preventative techniques aimed at reducing the incidence of infec-
tion by antimicrobial-resistant bacteria and the emergence and spread of antimicrobial-resistant 
strains. By employing a variety of prevention strategies, including proper personal hygiene, 
prescreening for carrier status before hospital admission, disinfection of hospital rooms, and 
careful monitoring of antimicrobial prescribing, marked progress can be achieved in the control 
of drug-resistant pathogens, which can translate into more effective antimicrobial therapy.
Keywords: infection prevention, antibiotic, personal hygiene, disinfection, microbial 
  surveillance, drug-resistant pathogen
Introduction
Antimicrobial drug resistance is a major international concern. While drug discovery 
is an important approach to solving current treatment voids and improving existing 
modalities, given the years of research and significant cost associated with   bringing 
new drugs into the market, the development of new drugs that target pernicious 
  drug-resistant microbes may not be the most effective strategy. Rather, a number of 
relatively simple strategies and behavioral modifications based on clinical studies 
and careful surveillance of hospital protocols and procedures appear to hold promise. 
However, despite the plethora of recommendations, antimicrobial resistance remains 
a multifaceted, major public health concern.1,2
The growing problem of antimicrobial  
drug resistance
Methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant 
  Enterococcus (VRE), Mycobacterium tuberculosis, Streptococcus pneumoniae and 
other pathogens have a significant impact on morbidity and mortality and are   considered 
a substantial threat to public health in the United States.3 Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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The US Surgeon General in the late 1960s, William H 
Stewart, allegedly stated ‘[it] is time to close the book on 
i  nfectious diseases and declare the war against pestilence 
won.’4 While this statement is now considered overly confident 
and erroneous, one can’t help but question why humans are not 
better equipped to face the microbial world. The answer likely 
lies in the fact that microbes have been evolving far longer 
than humans; nearly 3.5 billion years.5 Aiding their ability to 
adapt is the fact that bacteria can replicate their entire genome 
in 20–30 minutes, a task that takes humans 20–30 years to 
complete.3 Thus, microbes can arguably qualify as the most 
plentiful, diverse and adaptable species on the planet.3
While antibiotic research and development is one way 
to target the spread of microbial resistance, it is just as true 
that current drugs could be more efficacious if used more 
appropriately, with greater attention to their pharmacokinetic 
(PK) and pharmacodynamic (PD) properties and avoidance 
of overuse. In addition, measures such as proper hygiene and 
barrier precautions, environmental cleaning, prophylaxis and 
topical decolonization, and reduced antibiotic overuse can 
be very successful in ensuring the long-term preservation of 
antimicrobial efficacy.
The Centers for Disease Control and Prevention (CDC) 
estimates that the annual number of health care-associated 
infections in US hospitals is around 1.7 million. This   translates 
into roughly 99,000 deaths, which makes   hospital-acquired 
infections the leading cause of infectious death and one of the 
top 10 causes of death overall.6 MRSA, VRE and Clostridium 
difficile account for at least 350,000 of these infections and 
are responsible for approximately 12,000 deaths.7 The CDC 
estimates that drug-resistant i  nfections will result in an 
added cost in excess of US$3.5 billion per year.7 Antibiot-
ics currently available have been proven to be effective in 
clinical trials and settings. Appropriate use of antibiotics 
and   preventative measures can result in dramatic health care 
savings by eradicating drug-resistant microbes that arise due 
to careless antibiotic exposure.
Hygiene and barrier precautions
While multidrug-resistant microbes have emerged as a 
result of overprescribing and are often transferred between 
patients, health care workers represent an important source 
of   drug-resistant bacterial contamination. The CDC and the 
Society for Health care Epidemiology of America (SHEA) 
  guidelines recommend the minimal precautions of wearing 
gloves and gowns for health care workers when attending 
hospitalized patients that are infected with either MRSA 
or VRE.8,9
Several studies have examined the role of hand hygiene 
and uniform cleanliness in the spread of MRSA and VRE. 
The presence of MRSA or VRE on the gowns and/or gloves of 
health care workers can vary from 4% to 67%.10–14   Synder et al 
investigated the various risk factors for MRSA   contamination 
of gowns and/or gloves of health care   workers during every-
day clinical activities. The study involving 141 health care 
workers was conducted at the University of Maryland Medi-
cal Center, which has an infection control policy in place that 
includes hand washing with either an antimicrobial soap or 
an alcohol-based product before entering and after exiting a 
patient’s room, and the use of disposable gloves and gowns 
adorned prior to entry into a patient’s room. Samples from 
the hands, gloves and gowns of the workers were collected 
before and after nonemergency care of patients either infected 
or colonized by MRSA and/or VRE. Various environmental 
samples were also obtained.
Of the 137 health care workers that completed the study, 
24 (17.5%) acquired a drug-resistant microorganism on 
their gloves, gown or both after interacting with a patient 
that was colonized with either MRSA or VRE. Statistically 
significant risk factors for becoming contaminated with VRE 
or MRSA included attending to patients with a percutaneous 
endoscopic gastrostomy and/or jejunostomy tube (P , 0.05), 
contact with an endotracheal tube or tracheostomy site 
(P , 0.05), and contact with the head and/or neck of the 
patient (P , 0.05).
There was no significant correlation between the time 
spent in a patient’s room and acquisition of VRE or MRSA 
(P = 0.27), which suggested that greater time spent in a 
patient’s room does not necessarily place a health care worker 
at a greater risk of acquiring MRSA or VRE if the patient 
is infected. The study also showed that the environment 
does not always act as a reservoir for antimicrobial resistant 
pathogens. That the gloves and gowns of as many as 17.5% 
of health care workers were found to be contaminated with 
VRE and MRSA stresses the importance of these protec-
tive barriers. Clearly, it was relatively easy for a health care 
worker to acquire MRSA or VRE after coming in physical 
contact with a patient, particularly in the aforementioned 
risk-situations.
Wilson et al performed a meta-analysis of studies 
that addressed the issue of health care worker uniforms 
  serving as vectors for the transmission of infection, and the 
  effectiveness of home versus industrial laundering.15   Several 
  small-scale studies indicate that nurse uniforms indeed 
become   contaminated with microorganisms.11,16–21 A major 
limitation of most of these studies, however, is that the Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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degree of contamination and the distinction between acquired 
pathogens and environmental/skin flora was not determined 
or reported. One study did report that roughly one-third of 
the microorganisms detected on nurse uniforms originated 
from the flora of the wearer.17
Meta-analysis of the efficacy of domestic and industrial 
laundering revealed that domestic laundering reduces micro-
bial contamination by up to 109.22 One study in the literature 
compared home and industrial   laundering   processes and 
found no difference between the two   methods in terms of 
removing microbial contamination from   uniforms.23 Most of 
the available data on washing   conditions (ie, water tempera-
ture, duration, the use of bleach) was inconclusive. Overall, 
the general consensus based on these studies is that caution 
must be exercised when it comes to protection of patients 
and health care workers. Furthermore, uniforms cannot be 
treated as the only means of protection; gloves, gowns or 
plastic aprons should be considered, in addition to proper 
hand hygiene and garment removal.
Environmental cleaning
Hospital-acquired infections are difficult to treat, and can 
result in increased hospital length of stay (LOS), h  ealth 
care costs, and in some cases, mortality.24 Hayden et al 
i  nvestigated the effects of improved environmental   cleaning 
with and without strict enforcement of hand hygiene on 
the t  ransmission of VRE in a medical intensive care unit 
(MICU).1,25 The multistage intervention involved sequential 
implementation of an improved daily cleaning routine and a 
hand-hygiene campaign. In the first stage, a daily   cleaning 
routine was phased-in over a 30-day period (period 1) and 
then fully implemented for a second period, of 58 days (period 
2). The cleaning program consisted of wiping or mopping 
all accessible surfaces, with particular emphasis on surfaces 
most frequently touched by patients and health care   workers. 
Ventilator control panels were also cleaned daily. In the 
s  econd stage, a hand-hygiene campaign i  ncorporating the use 
of alcohol gel dispensers throughout common areas, within 
patient rooms, and at every room entrance was phased-in over 
a period of 21 days (period 3) and then continued for 82 days 
(period 4). Cultures obtained within 2 days of admission to 
the MICU were used to determine initial (baseline) VRE 
colonization rates.
Of the 748 patients involved in the study, 43 acquired 
VRE in the MICU. The acquisition rate in period 1 was 
33.47 cases per 1000 patient-days at risk, and then declined 
to 16.84, 12.09 and 10.40 cases per 1000 patient-days at 
risk in periods 2, 3, and 4, respectively. The detection rate 
of VRE in clinical cultures of samples obtained from the 
patients in the MICU decreased from 12.7 isolates per 
1000 patient-days in period 1 to 7.3 isolates per 1000 patient-
days in period 4.
Overall,  the  study  demonstrated  that  increased 
e  nvironmental cleaning is associated with a reduction 
in VRE-positive environmental cultures. Environmental 
c  leaning rates (number of sites cleaned divided by the 
  number of sites monitored) increased from 0.48 at baseline to 
0.87 during period 2, and although cleaning was not directly 
advocated after that point, the rate remained high for periods 
3 and 4. Similarly, contamination rates decreased before and 
after room cleaning (baseline, 0.15 and 0.1, respectively; 
period 2, 0.07 and 0.04, respectively). The acquisition rate 
of VRE in patients at baseline was 12.3%, and this decreased 
to 5.6% as the study progressed. The authors concluded 
that enforcing routine environmental cleaning procedures 
results in less surface contamination of VRE and a decline 
in VRE cross-transmission in a MICU with endemic high 
levels of VRE.
Hardy et al examined the relationship between 
e  nvironmental contamination and patient infection with 
MRSA, and found a positive correlation between rate of 
infection and contamination of environmental spaces.26 The 
study was carried out in a nine-bed general intensive care unit 
(ICU) described as ‘open’, with no side rooms. MRSA was 
isolated from the environment during every environmental 
screening and in most cases (23 of 24 screenings, 95.8%), 
at least one patient in the ICU was positive for MRSA. 
The rate of environmental contamination in the immedi-
ate   vicinity of patients colonized with MRSA was slightly 
elevated compared to the areas around noncolonized patients 
(25.4% vs 20.2%).
Using pulse-field gel electrophoresis to group MRSA 
isolates by similarity, it was shown that 25.4% of colonized 
MRSA patients occupied a bed space colonized with a MRSA 
strain of high similarity. Patients separated by great distances 
within the ICU ward harbored the same MRSA strain, and 
MRSA was present regardless of number of MRSA-infected 
patients admitted. Furthermore, patients admitted to the ICU 
after discharge of a MRSA patient were also able to acquire 
the pathogen after occupying a previously contaminated 
space. These results suggested the presence of a secondary 
reservoir of MRSA in addition to patients. Areas underneath 
the beds had the highest levels of MRSA contamination, 
in agreement with previous data showing that floors have 
the highest levels of MRSA contamination in areas where 
the microbe is endemic.11 Although floors are infrequently  Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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touched by patients or health care workers, they could become 
highly contaminated via dust movement from frequently 
touched surfaces.27 Indeed, MRSA carried on dust particles 
is capable of being aerosolized into particulate matter of a 
size in the respirable range.27
Huang et al carried out a retrospective cohort study of 
patients that had been admitted to eight different ICUs over 
a period of 2 years to determine whether transmission of 
drug-resistant bacteria was associated more highly with a 
prior room occupant who harbored a resistant organism or 
an contaminated inanimate object in the room.28
Patients who were assigned to a room that was   previously 
occupied by a MRSA carrier versus the room of a   previous 
non-MRSA patient had a significantly higher risk of   acquiring 
MRSA during their stay (3.9% vs 2.9%, P = 0.03). S  imilarly, 
patients who were assigned to a room that was previously 
occupied by a VRE carrier had a significantly higher risk 
of acquiring VRE during their stay than had they been 
assigned a non-VRE room (4.5% vs 2.8%, P = 0.001). The 
study   concluded that admission to an ICU room that was 
  previously occupied by a MRSA- or VRE-positive patient 
was   associated with an increased risk of acquiring an 
i  nfection. The increased risk amounted to less than 10% of 
all cases of ICU acquisition, and the population attributable 
risk was less than 2% among patients that were exposed. 
However, these results confirmed that patients who are not 
carriers or infected before admission can acquire MRSA or 
VRE during their hospital stay.
Prophylaxis and topical 
decolonization
S. aureus is a common microbe found often on the skin of 
humans. It is estimated that approximately one-third of the US 
population is colonized with S. aureus.29 The nose serves as 
the primary reservoir for S. aureus, and nasal carriers have an 
increased risk of acquiring an infection due to this   opportunistic 
pathogen.30 S. aureus infections are becoming increasingly com-
mon, and can account for up to 1% of all US hospital stays.31 
The burden of S. aureus infections on US hospitals in 2001 was 
estimated to be 2.7 million days of excess LOS, $9.5 billion 
in excess charges, and nearly 12,000 fatalities per year.31 The 
issue continues to escalate, prompting considerable research 
on S. aureus prophylaxis and eradication.
S. aureus is the leading cause of surgical site infection 
(SSI) and health care-associated pneumonia, and the second 
leading cause of nosocomial bacteremia in the USA.32 A study 
conducted from 1995 through 1998 by Perl et al showed that 
the use of a prophylactic agent, mupirocin, prior to   cardiac 
surgery can significantly decrease the rate of nosocomial 
infections due to S. aureus.33 Although this study showed no 
significant difference in the rate of SSI between the   mupirocin 
and placebo groups, there was a significant decrease in health 
care-associated infections of S. aureus among carriers treated 
with mupirocin (odds ratio = 0.49; P = 0.02).
Young et al conducted a cost-effectiveness analysis of three 
different preoperative treatment strategies for the prevention 
of postoperative health care-associated S. aureus infections 
among surgical patients.34 Strategy 1 consisted of screen-
ing patients for S. aureus and administering mupirocin to 
c  arriers (screen-and-treat strategy); strategy 2 consisted of no 
screening and the administration of mupirocin to all patients 
(treat-all strategy); and strategy 3 consisted of no screening 
and no treatment. Excess h  ospitalization costs attributable 
to health care-associated infections were   calculated based 
on published estimates of reported   hospitalization costs in 
the USA since 1990.
Both mupirocin treatment arms were associated with cost 
savings. The screen-and-treat strategy yielded a savings of 
US$102 per patient, while the treat-all strategy yielded a 
savings of $88 per patient. Either strategy would prevent 86 
infections per 10,000 patients undergoing surgery. The initial 
rate of S. aureus colonization was the greatest variable in the 
cost estimates. Higher colonization rates resulted in greater 
savings per 10,000 patients ($764,367 for a colonization rate 
of 19% vs $3,001,988 for a colonization rate of 55%).
A similar study examined the impact of adding 
  preadmission rapid testing for nasal carriage of S. aureus 
and any necessary subsequent decolonization therapy in 
patients scheduled for elective surgery.35 The 2003 edition 
of the Agency for Healthcare Research and Quality Nation-
wide Impatient Sample Database was used to generate epi-
demiological input data, and a literature-based estimate of 
the probability of a discharge diagnosis of positive S. aureus 
nasal   carriage was used. The analysis showed that the annual 
mean cost in   savings generated by performing a preadmission 
rapid test for S. aureus in all patients scheduled to undergo 
elective   surgery was $231,538,400. The mean number of 
hospital days would be reduced by 364,919, and a mean of 
935   in-hospital deaths per year due to S. aureus would be 
  prevented. A theoretical savings of over $230 million   dollars 
and the potential to significantly improve the health and 
safety of hospitalized patients strongly supports continued 
use and investigation of prophylactic strategies to combat S. 
aureus infection.
Simor et al examined the efficacy of intranasal   mupirocin 
administration, in combination with a chlorhexidine Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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  gluconate wash, oral rifampin, and doxycycline, for the 
treatment of MRSA infections.36 MRSA-positive patients 
were randomly assigned to treatment or no treatment groups. 
Those in the treatment group received a 7-day course of 
daily   administration of a 2% chlorhexidine gluconate/2% 
  mupirocin ointment (approximately 1 cm) applied to 
the a  nterior nares, plus rifampin 300 mg twice daily and 
  doxycycline 100 mg twice daily. Treatment was started within 
4 days of obtaining a positive culture for MRSA. The   primary 
outcome of the study was eradication of MRSA from all 
sample sites (anterior nares, perianal area, skin lesions, and 
catheters or other   medical device exit sites) 3 months after 
completion of therapy, or randomization for the non-treated 
group. The 3-month time point was chosen based on existing 
data   indicating that MRSA is eradicated for up to 90 days. 
In the treatment group, 74% (64 of 87) of the patients had 
negative MRSA cultures for all sites, as compared to 32% 
(8 of 25) in the nontreated patients, which translated into a 
relative risk of 1.55 (95% confidence interval). These results 
support the use of a fairly aggressive course of treatment for 
MRSA colonization that may be more appropriate for people 
who need to visit hospitals frequently owing to underlying 
medical conditions.37
PK and PD
Yet another facet of antimicrobial resistance is the PK and PD 
properties of different formulations of antibiotic.   Hoffman 
et al investigated the effects of an oral sustained-release 
  antimicrobial formulation on antimicrobial drug-resistance 
in the rat.2 The rationale for using oral sustained-release 
products includes the short half-life of most antimicrobial 
agents and the difficulty in attaining PD targets.38,39 However, 
orally-administered antibiotics have an often overlooked and 
unintended target – the natural microflora of the colon. In 
general, sustained-release formulations are associated with 
a larger portion of unabsorbed drug in the colon versus their 
immediate-release counterparts, resulting in unnecessary 
exposure of the colonic microflora to an antimicrobial agent, 
potentially facilitating the harboring of resistant bacteria in 
this region of the body.
The study used amoxicillin, a β-lactam commonly used 
for the treatment of aerobic Gram-positive organisms and 
some aerobic Gram-negative organisms. β-lactams have a 
short half-life and exhibit time-dependent killing kinetics. 
Importantly, the absorption window for β-lactams in rats 
mirrors that of humans.40 Following oral administration of 
amoxicillin, but not placebo, amoxicillin-resistant colonic 
bacteria were isolated from fecal samples, which suggested 
that an unabsorbed fraction of the antimicrobial agent reached 
the colon and facilitated the emergence of resistant bacteria. 
These undesirable effects were avoided by administration of a 
β-lactamase, which degraded the unabsorbed fraction before 
it passed into the upper colon. Thus, neutralization or inacti-
vation of a clinical excess of drug prevented the emergence 
of drug-resistant bacteria. These results   indicate that the risk 
of microbial resistance should be carefully   considered when 
developing or administering a sustained-release antimicrobial 
formulation.
One of the best examples of how PK and PD properties 
can modify outcomes is the class of drugs known as fluoro-
quinolones. Fluoroquinolones are second only to cefazolin as 
the most commonly prescribed antibiotic in US hospitals.41 
Stamey et al was one of the first to demonstrate the direct 
relationship between antibiotic under-dosing and the emer-
gence of microbial drug resistance.42 Using nalidixic acid 
to treat 100 strains of Enterobacteriaceae, the   investigators 
reported a direct increase in number of resistant strains with 
decreasing concentrations of drug. Since this   initial study, 
similar results using many other   fluoroquinolones have been 
reported.
When determining the optimal dosing regimen with 
  minimal induction of resistance for a class of   antibiotics, 
a   useful point of reference is the mutant prevention 
  concentration (MCP).43 The MCP is the concentration of 
drug required to prevent the occurrence of all   single-step 
mutations in a b  acterial cell population of at least 1010.44 
Dong et al i  nvestigated the effect of administering 
various fl  uoroquinolones at different concentrations on 
bacterial   colony growth.43 As antibiotic concentration 
increased,   colony number dramatically decreased, allowing 
  determination of the minimum inhibitory concentration 
(MIC). It is   presumed that bacteria that survive the first 
large decrease have acquired a first-step mutation. After 
the first decrease, there was a plateau, followed by a second 
dramatic decline in number of colonies surviving, indicat-
ing the MPC. Bacteria that survived despite the presence of 
the MPC most likely had acquired a second-step mutation. 
This work provides the basis for the concept of the ‘mutant 
selection window’,44 the range of antibiotic concentration 
between the MIC and MPC in which selective antibiotic 
growth may occur and resistant mutants selected. The 
mutant selection window has been determined for many 
fluoroquinolones and other   antibiotics. Careful use of this 
information when   prescribing can   optimize the effective-
ness of fluoroquinolones and m  inimize the emergence of 
resistant strains. Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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Madras-Kelly et al investigated the efficacy of an 
i  ntervention designed to decrease rates of nosocomial 
MRSA infection by encouraging decreased fluoroquinolone 
use.45 The intervention consisted of a flagged message that 
would appear on an electronic order-entry screen when 
fl  uoroquinolones were selected as a treatment antibiotic. 
The message consisted of SHEA guidelines for preventing 
  nosocomial transmission of multidrug-resistant strains of 
S. aureus and Enterococcus organisms and r  ecommendations 
for limiting the use of broad-spectrum antibiotics, p  articularly 
fluoroquinolones.8 Following the computer-generated prompt, 
subsequent changes in antibiotic prescribing, potential nonan-
tibiotic risk factors for MRSA infection, and frequency of 
nosocomial infection were recorded.
Total fluoroquinolone use decreased by 34% (129 vs 85 
defined daily doses per 1000 patient-days) and   levofloxacin 
use decreased by 50% (116 vs 58 defined daily doses 
per 1000 patient-days) following the intervention. These 
decreases were accompanied by increases in the use of 
linezolid and piperacillin-tazobactam, and a decrease in van-
comycin use. In general, there was an increase in β-lactam 
susceptibility rates among Staphylococcus species, and 
an increase in fluoroquinolone susceptibility rates among 
both Staphylococcus species and Gram-negative organisms 
f  ollowing the intervention. These results point to the use of 
caution in prescribing habits, with particular attention to 
correct dosing regimens.
Antibiotic overuse
The practice of medicine in the USA is focused primarily 
on the individual patient and not the health of the general 
  population. For example, a physician typically treats an 
  infection using a particular course of treatment   regardless 
of whether it has been linked to high levels of resistance.46 
This results in antibiotics often being   prescribed inappro-
priately. The prescription of broad-spectrum   antibiotics has 
been increasing, independent of infection type or indication, 
even in the midst of increased pressure to avoid antibiotic 
prescribing for common maladies.47–49
The Swedish Strategic Program for the Regional Use 
of Antimicrobial Agents and Surveillance of Resistance 
(STRAMA) was developed in 1994 in an attempt to 
  preserve the effectiveness of antimicrobial agents in Sweden. 
  Antibiotic use in Sweden had increased during the 1980s 
and early 1990s. Following detection of multidrug-resistant 
pneumococcal species in the early 1990s in young children, 
medical professionals made great efforts to prevent further 
spread of these malicious microbes. The effort initially 
targeted only pneumococcal species, but now encompasses 
many different microbes.
In 2008, Molstad et al published a summary of STRAMA’s 
first 10 years.50 The main objective of STRAMA is to contain 
antibiotic resistance at the national level. Between 1995 and 
2004, total antibiotic use defined as daily doses per 1000 
inhabitants per day (DDD) decreased by 15% (from 17.3 
to 14.6 DDD), and outpatient use decreased by 20% (from 
15.7 to 12.6 DDD). The number of prescriptions declined by 
23%, from 536 to 410 per 1000 inhabitants per year, with 
the largest decline observed in macrolides (65%). STRAMA 
illustrates that, through the coordinated effort of health 
care professionals, general antibiotic use and the spread of 
  antibiotic resistance can be minimized.
While the focus of much of the research on antibiotic 
management is on overuse and inappropriate use, Gross et al 
recently addressed the importance of not using antibiotics at 
all, specifically in the treatment of bacteriuria associated with 
urinary tract infection (UTI).51 A positive urine culture may 
indicate a serious condition such as pyelonephritis or cystitis, 
or benign or asymptomatic bacteriuria (ASB).51,52
The 2005 Infectious Disease Society of America 
  guidelines specifically state that there is no foreseen   benefit 
to screen for or provide antibiotic treatment of ASB in 
  certain subsets of patients (premenopausal women who are 
not pregnant, patients with diabetes, older patients living in 
the community or long-term care facilities, and patients with 
spinal cord injury or indwelling bladder catheters). Screening 
and treatment is recommended when the patient is pregnant 
or prior to surgery involving the urinary tract. Importantly, 
the guidelines state that eradicating the microorganisms 
can often be unsuccessful and only aid in the selection of 
more resistant microorganisms, such as extended-spectrum 
β-lactamase-resistant bacteria, vancomycin-resistant 
  enterococci, and others.52,53 Thus, the use of antibiotics to 
treat ASB should be discouraged to reduce ‘indiscriminate 
use’ of antimicrobial agents and the appearance of drug-
resistant bacteria.
Yet another strategy that has been tested for c  ombating 
antibiotic resistance is implementation of a monthly 
r  otation protocol in hospitals, particularly ICUs. Bennett 
et al   developed and tested a protocol at a surgical ICU 
that included a monthly rotation of four broad-spectrum 
  antibacterial agents, piperacillin/tazobactam, imipenem/
cilastin, ceftazidime, and ciprofloxacin.54 The primary 
  objective of the study was to determine the effectiveness of 
the antibiotic rotation protocol 1 year after implementation, 
as measured by the antibiotic susceptibility of Gram-negative Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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organisms isolated from patients. The study concluded that 
a monthly antibiotic rotation protocol improves antibiotic 
susceptibility rates of Pseudomonas aeruginosa, one of the 
most common nosocomial infectious agents. However, while 
the study demonstrated that antibiotic cycling is successful 
1 year after protocol implementation, it did not address 
long-term efficacy.
Cosgrove et al reported the results of an innovative 
method of postprescription review and physician feedback for 
c  ontrolling institutional use of antibiotics.55 For patients on 
antimicrobial therapy for 48–72 hours, postprescription review 
determines the appropriateness of the course of t  reatment 
after additional clinical and microbiologic data has become 
available. At this point in time, a r  ecommendation is made to 
either modify or cease treatment. The study was c  arried out 
at Johns Hopkins Hospital, which uses a   preapproval   system 
for specific broad-spectrum and reserve   antimicrobials. 
The   investigators developed a s  oftware p  rogram called 
  Antimicrobial Management   Program (AMP) reporter, which 
enabled automated searches of stored   pharmacy data (ie, anti-
biotic course, start and stop dates/times, ordering   clinician) 
and institutional   microbiologic data for patients within the 
  previous 30 days. Cases that were   identified by the AMP with 
in reporter as   involving one or more restricted   broad-spectrum 
or reserve antimicrobial agents were reviewed by an i  nfectious 
d  isease pharmacist or   attending physician, and feedback 
was provided to the   primary p  hysician or patient care team 
in one of several forms: direct call to the primary clinician, 
an electronic text message to the primary clinician, or a note 
placed on the patient’s medical record. The effectiveness of 
  antimicrobial management with regards to intervention rate 
and i  mplementation of r  ecommended changes using the 
postprescription review process was compared to the prior 
approval system.
The investigators found that postprescription review 
was superior to prior approval in terms of intervention rate, 
which was defined as number of courses of therapy requiring 
a recommendation divided by the total number of courses of 
therapy reviewed (57%–78% vs 5%, respectively). In 85% 
of the cases reviewed, the recommendations were to either 
narrow or cease therapy, and overall, 71.9% of physicians 
followed the recommendations. There was little difference in 
compliance with postprescription review re  commendations 
made by phone, page, or notes on the medical record. An 
important limitation of the study, however, was the lack of 
randomization when selecting cases that received the inter-
vention. Regardless, the results support the use of postpre-
scription review as a tool to reevaluate and cease if necessary 
broad-spectrum empirical therapy that is often prescribed 
in the absence of microbiologic findings, thus potentially 
  reducing the overall use of antimicrobial therapy.56
Conclusion
The emergence of drug-resistant bacteria is to some extent an 
inevitable consequence of the patterns of use of antibiotics 
in society today. Given the time and cost required to bring 
new, more effective antimicrobial therapeutics to market, 
drug discovery may not be the most effective approach to 
limiting antimicrobial resistance. Rather, there is substan-
tial evidence to support that more appropriate and careful 
use of antibiotics, with particular attention to the variable 
PK and PD properties of different formulations, and even 
avoiding antibiotic treatment altogether in some cases, can 
significantly decrease or limit drug-resistant bacteria. In 
addition, relatively inexpensive and simple measures, such 
as microbial surveillance and prophylaxis, proper hygiene, 
the use of protective barriers, and environmental cleaning 
can translate into major savings in health care-related costs, 
and significant improvements in patient health and quality 
of care. While Stewart’s ‘war on pestilence’ certainly is not 
won, the task is not insurmountable, but will require a shift 
in behavior and attitudes among health care providers and 
patients.
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